RNTX · Rein Therapeutics Inc
United States · RS rating 24 · As of 2026-11-03
| Price | 0.67 USD |
|---|---|
| 1-day change | +5.1% |
| RS rating (overall / 1M / 3M / 12M) | 24 / 22 / 52 / 18 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 22 / 6 / 42 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +47.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +64.5% |
| Market cap (USD) | $51.6M |